DexCom Inc. ($DXCM) Stock Forecast: Down 5.0% Today

What is DexCom Inc.?

DXCM (DexCom Inc.) is a company specializing in continuous glucose monitoring systems, playing a crucial role in diabetes management. The stock has experienced a significant bearish movement today.

Why is DexCom Inc. going down?

DXCM stock is down 5.0% on May 14, 2026 15:40

• Despite reporting strong Q1 2026 earnings with a 15% revenue growth and positive market reaction, the stock saw a 4.2% decline. This could be due to profit-taking by investors after a period of growth.
• The insider selling of $0.2 million might have contributed to a lack of near-term confidence among investors, impacting the stock price negatively.
• The overall bearish movement of DXCM could also be influenced by broader market trends or sector-specific factors affecting medical device companies, despite Dexcom's strong position in the CGM market and international expansion efforts.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

Dexcom stock (US2521311074): Q1 2026 earnings beat with 15% revenue growth

Dexcom reported strong Q1 2026 earnings, with revenue reaching $1.19 billion, a 15% increase year-over-year, and EPS at $0.52, up significantly from $0.27. The company's net income also saw an 89% jump to $199.5 million, surpassing expectations and leading to a positive stock performance. Dexcom, a leader in continuous glucose monitoring systems, continues to drive growth through increasing adoption of its technology and innovation in diabetes management.

https://www.ad-hoc-news.de/boerse/news/ueberblick/dexcom-stock-us2521311074-q1-2026-earnings-beat-with-15-percent/69335181

VIRGINIA RETIREMENT SYSTEMS ET Al Sells 35,400 Shares of Medtronic PLC $MDT

Virginia Retirement Systems Et Al reduced its stake in Medtronic PLC by 30% in the fourth quarter, selling 35,400 shares and retaining 82,600 shares valued at approximately $7.94 million. Additionally, Medtronic EVP Harry Skip Kiil sold 52,524 shares for $5.13 million, decreasing his position by over 61%. Despite recent stock weakness and some negative sentiment, analysts maintain a "Moderate Buy" consensus for Medtronic, which recently beat EPS and revenue estimates and pays a quarterly dividend of $0.71 per share.

https://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-sells-35400-shares-of-medtronic-plc-mdt-2026-05-14/

Bank Julius Baer & Co. Ltd Zurich Has $96.23 Million Position in Medtronic PLC $MDT

Bank Julius Baer & Co. Ltd Zurich increased its stake in Medtronic PLC by 1.9% in the fourth quarter, bringing its total holding to 999,638 shares valued at $96.23 million. Medtronic (NYSE: MDT) recently reported strong earnings, exceeding analyst expectations with an EPS of $1.36 and revenue of $9.02 billion, and also declared a quarterly dividend of $0.71 per share. Despite positive developments like new leadership and pipeline momentum, the stock has been under pressure, trading near its 1-year low, reflecting mixed sentiment among analysts who currently rate it a "Moderate Buy."

https://www.marketbeat.com/instant-alerts/filing-bank-julius-baer-co-ltd-zurich-has-9623-million-position-in-medtronic-plc-mdt-2026-05-14/

DexCom Inc (DXCM) Shares Fall 4.2% -- What GF Score of 89 Tells Investors

DexCom Inc (DXCM) shares dropped 4.2% to $58.57, marking a 30.4% decline over the past year. Despite this, its GF Score of 89/100 and a GF Value of $101.86 suggest the stock is significantly undervalued, presenting a potential opportunity. However, recent insider selling of $0.2 million raises questions about near-term confidence among insiders.

https://www.gurufocus.com/news/8856637/dexcom-inc-dxcm-shares-fall-42-what-gf-score-of-89-tells-investors

Dexcom stock (US2521311074): Q1 2026 earnings beat with 15% revenue growth

Dexcom reported strong Q1 2026 results, with revenue up 15% to $1.19 billion and earnings per share increasing to $0.52. This performance, driven by continuous glucose monitoring system sales and international expansion, led to a positive reaction from investors. The company's strong position in the growing CGM market and its US market dominance are highlighted as key factors for its success.

https://www.ad-hoc-news.de/boerse/news/ueberblick/dexcom-stock-us2521311074-q1-2026-earnings-beat-with-15-percent/69325686

Trending Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.6% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 6.4% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 18.8% Today

CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.0% Today

GoPro Inc. ($GPRO) Stock Forecast: Up 10.0% Today

Silver ($XAG) Commodity Forecast: Down 5.1% Today

Whirlpool Corporation ($WHR) Stock Forecast: Up 5.0% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.2% Today

Wix.com Ltd. ($WIX) Stock Forecast: Down 5.9% Today

The Boeing Company ($BA) Stock Forecast: Down 5.0% Today

DexCom Inc. Price History

03.01.2026 - DXCM Stock was down 1.8%

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

14.04.2026 - DXCM Stock was down 5.0%

• Despite reporting strong Q1 2026 earnings with a 15% revenue growth and positive market reaction, the stock saw a 4.2% decline. This could be due to profit-taking by investors after a period of growth.
• The insider selling of $0.2 million might have contributed to a lack of near-term confidence among investors, impacting the stock price negatively.
• The overall bearish movement of DXCM could also be influenced by broader market trends or sector-specific factors affecting medical device companies, despite Dexcom's strong position in the CGM market and international expansion efforts.

13.04.2026 - DXCM Stock was down 2.5%

• Despite strong Q1 2026 earnings with a 15% revenue growth, Dexcom's stock experienced a bearish movement.
• The positive investor reaction to Dexcom's performance may have already been factored into the stock price, resulting in profit-taking and a subsequent bearish trend.
• The increase in Insulet stock after Benchmark initiated coverage might have diverted attention and investment from Dexcom, affecting its stock performance.
• The rise in stake in Northrop Grumman Corporation by Virginia Retirement Systems ET Al and favorable news about Medtronic PLC may have redirected investor focus from Dexcom, contributing to its bearish movement.

01.04.2026 - DXCM Stock was up 6.0%

• DexCom (DXCM) reported impressive Q1 2026 financial results, with revenue exceeding expectations and driven by strong demand for its CGM products, particularly the G7 15-day system.
• The company's significant margin expansion and raised profitability guidance showcased strong operational efficiencies and market reception, contributing to the bullish movement in the stock.
• Despite concerns about sustained margin expansion and potential revenue growth deceleration, DexCom's strategic initiatives and positive outlook for the year contributed to investor confidence and the bullish market movement.

27.02.2026 - DXCM Stock was down 6.2%

• The amendment filed by a major institutional investor, stating it no longer beneficially owns any shares of DXCM, might have raised concerns among investors, leading to a sell-off.
• DXCM underperforming compared to its competitors and the broader market could have contributed to the bearish movement, as investors may have shifted their focus to other more promising opportunities.
• Despite Dexcom's impressive Q4 earnings and institutional buying interest, the overall negative sentiment in the market, coupled with concerns about the company's future growth prospects amidst competition and regulatory hurdles, likely weighed down on the stock price.

27.02.2026 - DXCM Stock was down 5.9%

• DXCM's stock price saw a considerable decrease in line with major indices like the S&P 500 and Dow Jones Industrial Average. This decline was influenced by rising uncertainties related to the U.S.-Iran conflict and impending policy decisions by the Trump administration.
• Despite DXCM exhibiting robust Year-over-Year EBITDA Growth of 52.52% and being deemed significantly undervalued, some investors may have exercised caution due to certain warning signals identified in the analysis.
• The recent disclosure by Vanguard Group, revealing no holdings of DXCM common stock subsequent to an internal reshuffling, may have further dampened investor sentiment towards the company.
• DXCM's underperformance in comparison to its competitors on Thursday and the conclusion of a two-day positive streak could have also played a role in the stock's downward trajectory, particularly amid the widespread market declines observed.

05.02.2026 - DXCM Stock was down 1.7%

• DexCom's stock witnessed a downturn despite surpassing analyst projections with its quarterly earnings. This drop may be linked to significant sell-offs made by Fisher Asset Management LLC.
• While institutional holdings from leading firms like Vanguard, MFS, and Picton Mahoney Asset Management saw an increase, it was insufficient to counterbalance the impact of Fisher Asset Management's divestment, leading to a negative trend in the stock price.
• Analysts have maintained a "Moderate Buy" consensus on DexCom, with an average target price of $85.18. This suggests continued faith in the company's prospects, even amidst ongoing market fluctuations influenced by institutional trading.

29.03.2026 - DXCM Stock was down 5.2%

• The launch of Dexcom Academy, a new educational platform for healthcare professionals, while a positive development for the company, may not have been sufficient to offset the bearish sentiment in the market.
• Competitor news from Tandem Diabetes Care receiving FDA clearance for its automated insulin delivery technology for pregnancy in Type 1 Diabetes could have potentially shifted investor focus away from Dexcom.
• Overall, the bearish movement in Dexcom's stock today could be attributed to a combination of market factors, including competition in the diabetes device market and general market sentiment impacting the healthcare sector.

29.03.2026 - DXCM Stock was down 5.3%

• Today's downward movement in DexCom's stock could be due to some investors selling off shares to realize profits after a period of price appreciation.
• Heightened volatility in DXCM's stock price leading up to the Q1 earnings announcement might be driven by market expectations.
• Despite positive industry sentiments, external factors such as market conditions or concerns about profit margins could have contributed to the bearish trend observed in DXCM today.

13.01.2026 - DXCM Stock was up 8.3%

• DexCom's stock price saw an 8.4% increase following the company's surpassing of Q4 earnings and revenue expectations, demonstrating robust financial performance and market confidence.
• Analysts have revised upwards their price objectives for DXCM, with targets raised to $85.05 by Mizuho and $90.00 by BTIG, indicating positive sentiment and potential for further advancement.
• The successful launch of innovative products like the DexCom G7 15-day system and DexCom Smart Basal, alongside opportunities for expansion into international markets, have contributed to the positive market trend.
• Although encountering short-term challenges like trading below moving averages and a high P/E ratio, DexCom's strong financial position, optimistic market growth outlook, and upcoming catalysts point towards a bright future for the company.

13.01.2026 - DXCM Stock was up 7.4%

• Despite DexCom's strong financial performance, including beating Q4 earnings and revenue estimates, the stock experienced a slight fall in after-hours trading. This could be due to profit-taking by investors after a recent surge in the stock price.
• The anticipation of expanded Medicare coverage for CGMs for Type 2 diabetes patients is a positive development for DexCom, indicating potential growth opportunities in a new market segment.
• The company's 2026 revenue forecast falling slightly below analysts' expectations may have contributed to some investor uncertainty, leading to the mixed market movement despite the positive earnings beat.
• Overall, the bullish movement in DexCom's stock today could be attributed to the company's strong financial performance, anticipation of expanded market opportunities, and positive analyst reactions, despite some lingering concerns about revenue forecasts.

13.01.2026 - DXCM Stock was up 5.2%

• The positive movement in DXCM stock today is driven by the impressive Q4 performance and optimistic outlook shared during the earnings call.
• Mizuho's increase in price targets and "Buy" ratings maintained by Wells Fargo and Stifel reflect favorable analyst sentiment and confidence in the company's future growth potential.
• Despite some immediate challenges like trading below moving averages and a high P/E ratio, investor confidence remains high due to DXCM's innovative products like the DexCom G7 15-day system and DexCom Smart Basal, as well as substantial international expansion opportunities.
• Anticipated catalysts in 2026, such as potential Medicare coverage and new product launches, contribute to the positive market sentiment surrounding DXCM, positioning it as a top choice in the diabetes sector and potentially undervalued per InvestingPro's Fair Value assessment.